Nabriva Therapeutics plc Overview
Get informed when a big investor buys or sells
+ Follow1250.52%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, NBRVF shows a ROE of 1250.52%. That is above the Healthcare sector average of -75.84%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about -75.84%. Nabriva Therapeutics plc is at 1250.52%, which is higher that average. That is roughly 1749.0% above the sector mean. Use the comparison chart on this page to see how NBRVF stacks up against individual peers as well.
Check the historical chart to see whether NBRVF's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Nabriva Therapeutics plc with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Nabriva Therapeutics plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 1250.52%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about -75.84%, while NBRVF is at 1250.52%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
